Clinical Trials Sponsored by Acceleron Pharma, Inc

Total 2347 results

Tceleron Therapeutics, Inc.

Terminated

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States
Tceleron Therapeutics, Inc.

Terminated

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

Hypertension, Pulmonary

United States, Belgium, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, Poland, Canada
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

Pulmonary Arterial Hypertension

United States, Belgium, France, Germany, Spain, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Korea, Republic of, Netherlands, Portugal, Serbia, Taiwan, Brazil, Canada, Czechia, Italy, New Zealand, Sweden, S... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (SOTERIA)

Pulmonary Arterial Hypertension | PAH

United States, France, Germany, Spain, Sweden, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Serbia, Taiwan, United Kingdom, Brazil, Canada, B... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Pulmonary Arterial Hypertension

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Serbia, Spain, Sweden, Switzerland, United Kingdom
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (ZENITH)

Pulmonary Arterial Hypertension

France, Germany, United States, Australia, Belgium, Canada, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

Systemic Sclerosis With and Without Interstitial Lung Disease

United States, Canada, Italy, Switzerland
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Recruiting

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Beta-Thalassemia

United States, Turkey, Italy, Thailand, Germany, Greece
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Completed

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia (BEYOND)

Thalassemia

United States, Greece, Italy, Lebanon, Thailand, United Kingdom
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Completed

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

Anemia

United States
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)

Pulmonary Arterial Hypertension

Spain, United States, Israel, Australia, Germany, United Kingdom, France, Brazil
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Beta Thalassemia

Beta-Thalassemia

Greece, Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of ACE-2494 in Healthy Subjects

Healthy Volunteers

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Muscular Atrophy

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Muscle Loss

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth Disease

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Phase 1 Study of ACE-083 in Healthy Subjects

Musculoskeletal Diseases

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

B-Thalassemia

Italy, Greece
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 in Healthy Postmenopausal Women

Anemia

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (SPECTRA)

Pulmonary Arterial Hypertension

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Charcot-Marie-Tooth Disease | Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

Osteoporosis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

Beta-Thalassemia | Erythrocyte Transfusion

United States, Israel, Australia, Turkey, Taiwan, Malaysia, United Kingdom, Canada, Thailand, France, Lebanon, Italy, Bulgaria, Greece, Tunisia
gicare Pharma Inc.
Algorithme Pharma Inc

Completed

Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

Pain | Cancer | Colonic Disease

Canada
Astellas Pharma Inc
Astellas Pharma US, Inc.; Advanz Pharma

Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Atrial Fibrillation | Atrial Flutter

Poland, United States, Canada, Argentina, Denmark, India
Astellas Pharma Korea, Inc.

Recruiting

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Korea, Republic of
Astellas Pharma China, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Liver Transplantation | Kidney Transplantation

China
Astellas Pharma China, Inc.

Completed

A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Liver Transplantation | Kidney Transplantation

China
Astellas Pharma China, Inc.

Completed

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Kidney Transplant

China
Astellas Pharma China, Inc.

Completed

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause (Moonlight 3)

Hot Flashes

China
Astellas Pharma China, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause (Moonlight 1)

Hot Flashes

Korea, Republic of, China, Taiwan
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Astellas Pharma Korea, Inc.

Completed

Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) (POST-TURP)

Overactive Bladder | Benign Prostate Hyperplasia | Transurethral Resection of Prostate | Photoselective Vaporization Prostatectomy

Korea, Republic of
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients (COSMOS)

Kidney Transplant

Korea, Republic of
Astellas Pharma China, Inc.

Completed

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Lupus Nephritis

China
Astellas Pharma China, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

Healthy Volunteers

China

Clinical Trials Sponsored by Acceleron Pharma, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations